Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
Both are riding the wave of major clinical wins
Via
The Motley Fool
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).
Via
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Via
Benzinga
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
November 28, 2022
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.
Via
Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...
Via
Benzinga
Why Is Biogen (BIIB) Stock Up 40% Today?
September 28, 2022
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors.
Via
InvestorPlace
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
This pair of stocks are bucking the trend and they could climb even higher.
Via
The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
Via
Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Via
Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.
Via
Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
October 29, 2022
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.
Via
The Motley Fool
Is Biogen a Buy After It Boosted Guidance?
October 26, 2022
There's a much bigger story for this biotech than its improved 2022 outlook.
Via
The Motley Fool
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
October 25, 2022
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month.
Via
Investor's Business Daily
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
October 24, 2022
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing
Via
Benzinga
3 Alzheimer's Therapy Stocks to Invest in
October 21, 2022
Alzheimer's treatments could make a big winner of these stocks.
Via
The Motley Fool
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
Hey Biogen Investors, Don’t Chase BIIB Stock!
October 05, 2022
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.
Via
InvestorPlace
2 Signals to Watch Before Buying SAVA Stock
October 05, 2022
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.
Via
InvestorPlace
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
September 28, 2022
Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring.
Via
InvestorPlace
Why Is Acumen (ABOS) Stock Up 95% Today?
September 28, 2022
Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company.
Via
InvestorPlace
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
Via
Benzinga
Why Acumen Pharmaceuticals Stock Is Soaring Today
September 28, 2022
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink:
Via
Benzinga
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
September 28, 2022
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target.
Via
InvestorPlace
Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28
September 28, 2022
Bloomberg
Via
Benzinga
What In The World Is Going On With Biogen (BIIB) Shares?
September 28, 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co.
Via
Benzinga
Why Cassava Sciences Shares Are Soaring Higher
September 28, 2022
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co.
Via
Benzinga
Why Biogen Stock Is Up 40% Today
September 28, 2022
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday.
Via
Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.